Drug Trial Radar · NCT04411836
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine
Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
960
Actual
Start
Apr 25, 2021
Primary completion
Sep 30, 2024
Study completion Sep 30, 2024
Sponsor
- Lead sponsor
- Menzies School of Health ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Melbourne; National Centre for Parasitology, Entomology and Malaria Control, Cambodia; Mahidol Oxford Tropical Medicine Research Unit; Ethiopian Public Health Institute; Universitas Sumatera Utara; Arba Minch University; Aga Khan University
- First posted
- Jun 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Health care facility based, randomized, controlled, open label, superiority trial with 3 arms
Conditions
- Vivax Malaria
- Plasmodium Vivax
- Malaria, Vivax
- Malaria Relapse
Interventions
TafenoquineDrug
patients are treated with schizontocidal treatment plus a single dose of Tafenoquine (TQ).
PrimaquineDrug
patients are treated with schizontocidal treatment plus high dose PQ (total dose 7 mg/kg) unsupervised over 7 days (PQ7)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence risk any P vivax PQ7 / PQ14Time frame: 6 months
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
Chambak Health Center
Kampong Speu, Cambodia
Siem Pang Health Centre
Stung Treng, Cambodia
Kravanh District Hospital
Pursat, Pursat, Cambodia
Arba Minch General Hospital
Arba Minch, Ethiopia
Tanjung Leidong Health Center
Labuhanbatu, Sumatera, Indonesia
Aga Khan Hospital Karachi
Karachi, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.